Expedia Group (NasdaqGS:EXPE) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsAriane Gorin - CEOEric Sheridan - Managing DirectorLee Horowitz - Co-Head of Internet Equity ResearchMark Mahaney - Senior Managing DirectorNaved Khan - Managing DirectorRob Bevegni - VP of Investor RelationsScott Schenkel - CFOConference Call ParticipantsConor Cunningham - Director and Travel and Transports AnalystDeepak Mathivanan - Senior Equity Research AnalystJed Kelly - Managing Director and Equity Re ...

Financial Data and Key Metrics Changes - Fourth quarter revenue reached $122 million, a 30% increase year-over-year, with 40% from systems and 60% from recurring revenue [5][10] - Full year revenue for 2025 was $453 million, up 13% year-over-year, indicating a market recovery trajectory [6][10] - Gross margin for Q4 was 40.8%, lower than guidance due to one-time inventory charges [11] - Cash and investments increased by $286 million during Q4, totaling $484 million at year-end [12] Business Line Data and Key Metrics Changes - Recurring revenue grew 4% quarter-over-quarter and 25% year-over-year, representing about 60% of total revenue in Q4 [4][5] - Systems demand increased 47% quarter-over-quarter, driven by higher equipment orders from major global customers [4] - The top ten customers accounted for approximately 63% of Q4 bookings, indicating healthy diversification [5] Market Data and Key Metrics Changes - Test utilization trends improved, with estimated utilization at 76% by the end of December, with computing at 78% and automotive at 75% [7] - Increased activity noted in automotive and industrial semiconductor sectors, alongside strong demand from RF and connectivity device customers [4][9] Company Strategy and Development Direction - The company is focusing on high-performance computing, HBM memory, and AI-related high-growth opportunities [11][12] - A strategic convertible notes offering was completed to strengthen the balance sheet and support strategic initiatives [12] - The company aims to support R&D investments enabling design wins in compute markets, including AI data center infrastructure [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating regional shifts and aligning with customers investing in long-term technology transitions [9] - The outlook for Q1 2026 anticipates revenue to be seasonally flat with Q4, with recurring revenue expected to represent about 60% of total revenue [14] - Management expects continued growth in 2026, building on the 13% revenue growth in 2025 [35] Other Important Information - The company secured significant orders for new products, including a high-performance thermal configuration of the Eclipse handler and a multi-unit order for a new handler targeting automotive and AI device tests [8][9] - The company has a solid risk balance profile due to low direct exposure to China and strong customer diversification across North America, Europe, and Asia [9] Q&A Session Summary Question: Order activity in Q4 - Management noted systems orders were up 47% quarter-over-quarter, with recurring orders up 34% quarter-over-quarter, indicating strong demand [18][20] Question: Revenue from Neon high bandwidth memory - The company exited 2025 with $11 million in HBM revenue and forecasts $15 million to $20 million for 2026 [22] Question: Eclipse activity and capacity - Management confirmed capacity to meet demand for the Eclipse handler, with expectations for increased shipments in the second quarter [25][26] Question: Customer activity changes - Management observed increased demand from traditional customers and strong forecasts for the Eclipse product line in compute and mobile applications [34] Question: IDM vs. OSAT performance - Utilization rates for IDMs were slightly higher than OSATs in Q4, with expectations that OSATs may see faster growth in the first quarter [50]

Vertex Pharmaceuticals (NasdaqGS:VRTX) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBrian Abrahams - Managing Director and Global Sector Head of Healthcare Research Full-timeCharlie Wagner - EVP, COO, and CFOCory Kasimov - Senior Managing DirectorDuncan McKechnie - EVP and Chief Commercial OfficerEvan Seigerman - Managing Director and Head of Healthcare ResearchGeoff Meacham - Managing DirectorMichael Yee - Global Head of Biotechnology Research and Managing DirectorReshma Kewalram ...

Dexcom (NasdaqGS:DXCM) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsDavid Roman - Managing DirectorJake Leach - President and CEOJereme Sylvain - CFOJoanne Wuensch - Managing DirectorJosh Jennings - Managing DirectorMarie Thibault - Managing DirectorMatt Taylor - Managing DirectorRichard Newitter - Managing DirectorSean Christensen - VP of Finance and Investor RelationsTravis Steed - Managing DirectorZachary Day - Equity Research AssociateConference Call ParticipantsBrandon Vazque ...

SPS Commerce (NasdaqGS:SPSC) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsChad Collins - CEOIrmina Blaszczyk - Director of Investor RelationsKim Nelson - CFOConference Call ParticipantsChris Quintero - Equity Research AnalystDylan Becker - Equity Research AnalystGeorge Kurosawa - Equity Research AnalystJeff Van Rhee - Equity Research AnalystLachlan Brown - AnalystMatt VanVliet - Equity Research AnalystMatthew Kikkert - Associate AnalystNehal Chokshi - Equity Research AnalystScott ...

CVRx (NasdaqGS:CVRX) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsJared Oasheim - CFOKevin Hykes - President and CEOMike Vallie - Healthcare Investor Relations Managing DirectorConference Call ParticipantsChase Knickerbocker - Senior Equity Research AnalystFrank Takkinen - Senior Research AnalystJohn Young - Research AnalystLily Lozada - Research AnalystMax Smock - Equity Research AnalystNone - AnalystOperatorWelcome to the CVRx Q4 2025 Earnings Call. At this time, all participant ...

Sensus Healthcare (NasdaqCM:SRTS) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsAnthony Vendetti - Executive Managing DirectorBen Haynor - Managing Director of Medical Technology ResearchJavier Rampolla - CFOJoe Sardano - Chairman and CEOMichael Sardano - President & Chief Commercial OfficerTirth Patel - VPOperatorGood afternoon, and welcome to the Sensus Healthcare Fourth Quarter and Full Year 2025 Financial Results Conference Call. All participants will be in listen-only mode. Sh ...

Pinterest (NYSE:PINS) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsAndrew Somberg - VP of Investor Relations and TreasurerBill Ready - CEOBrian Nowak - Managing DirectorEric Sheridan - Managing DirectorJulia Donnelly - CFORon Josey - Managing DirectorConference Call ParticipantsColin Sebastian - Baird logo Managing Director and Senior Research Analyst for Internet and Digital MediaDoug Anmuth - Managing Director and Internet AnalystJustin Patterson - Managing Director and Equity R ...

Aethlon Medical (NasdaqCM:AEMD) Q3 2026 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsJim Frakes - CEO and CFOSteven LaRosa - CMOConference Call ParticipantsJeremy Pearlman - AnalystMarla Marin - AnalystRK - AnalystOperatorGood day, and welcome to the Aethlon Medical third quarter fiscal 2026 earnings and corporate update conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero ...

Forrester Research (NasdaqGS:FORR) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsCarrie Johnson - Chief Product OfficerChris Finn - CFOChristophe Favre - Chief Sales OfficerEd Morris - VP of Corporate Development and Investor RelationsGeorge Colony - CEO and ChairmanNone - Company RepresentativeConference Call ParticipantsAndrew Nicholas - Equity Research AnalystAnja Soderstrom - Equity Research AnalystVincent Colicchio - Equity Research AnalystOperatorGood afternoon, and thank you ...